Business Wire

CA-TRIVVER

14.5.2018 10:02:10 CEST | Business Wire | Press release

Share
Trivver Launches Token Sale to Encourage Adoption and Development of Extended Reality Technology

Trivver , the premiere advertising exchange for Extended Reality (XR) environments including 3D, virtual reality, mixed reality and augmented reality, today announced that it will launch the sale of up to 100 million Trivver Tokens (TRVR) to accelerate the adoption, commercialization and monetization of XR technology across devices and industries for all stakeholders in the ecosystem – including content publishers, advertisers, brands, agencies and consumers.

Current 2D advertising tactics like pop-ups, banners, video and interstitials are highly disruptive to immersive XR experiences, leading to limited advertiser adoption of XR and reduced monetization opportunities for XR developers and publishers. Placing ads organically within the natural settings of XR environments is the answer, but the current processes that developers, publishers and advertisers use to execute this strategy is tedious and costly, as ads and objects need to be manually resized to fit each unique location. With Trivver’s suite of patented technology, including its core Smart Object Technology, developers are able to create and deliver native advertising directly into XR environments. This approach enables advertisers to create contextual, integrated XR ad campaigns to engage consumers in a unique and impactful way and gives publishers the opportunity to efficiently monetize their XR content.

“We believe in the exponential possibilities of XR and in the profound, lasting and global impact of this technology,” said Joel LaMontagne, CEO of Trivver. “We are passionate about driving XR adoption among consumers and within the enterprise. Our goal is to enable publishers and developers in the XR space to fund themselves through advertising and encourage the improvement of technology that enhances XR experiences for consumers. We’re also making it easier for advertisers to promote their brand in the XR space through seamless product placement – delivering relevant and interesting content to engage their users.”

In order to drive XR adoption and momentum, Trivver launched its pre-sale of TRVR tokens, which can be purchased with a bonus until June 5, 2018. The public token sale begins on June 8, 2018 and will close on July 7, 2018. The public sale will aim to raise $35 million, with the pre-sale accounting for up to $5 million.

Token Sale Details:

  • Under the terms of the sale, 1 ETH is equivalent to 750 TRVR (1 TRVR ~ 0.00133 ETH) and a hard cap of 100 million TRVR tokens are available for purchase of the finite supply of 200 million total TRVR.
  • All available TRVR will be issued during the distribution period, of which, 50 percent will be allocated to the public and 50 percent will be allocated to the reserve to be held by the company and used to stimulate growth in the Trivver XR advertising ecosystem by rewarding participants with TRVR.
  • All TRVR not distributed will be burned.

TRVR is the currency for the Smart Object Economy. Trivver’s patented Branded Smart Objects (BSOs) are 3D objects with product information (SKU data, coupons, social media links etc.) that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment. Trivver’s BSOs send valuable viewability and user engagement metrics back to the advertiser that will result in the best ROI.

Trivver launched its token sale in order to accelerate the build out of its Smart Objects catalog and will incentivize developers to participate through a system of rewards and payments of TRVR. Developers can earn TRVR for building and adding smart objects to the catalog. They can also use TRVR to list the smart object in Trivver’s inventory and establish authorship of the object. As the author, developers will receive royalties paid in USD from Trivver whenever revenues are generated by the smart object - from a publisher using it to build XR content or by an advertiser using it for future XR ad campaigns.

The Trivver platform is currently in beta and the company has already seen significant interest, announcing upcoming pilot programs in collaboration with WayFair and Cannon.

To learn more about Trivver and to participate in the token sale, visit: https://www.trivver.com/tokensale or join the conversation on Telegram to speak directly with the project’s founders and developers: https://t.me/trivvertokensale . Download the token sale whitepaper at: https://www.trivver.com/docs/Trivver_Whitepaper.pdf .

About Trivver

Trivver is the premiere advertising exchange for Extended Reality (XR) environments – 3D, virtual reality, mixed reality and augmented reality. The Trivver platform makes creating and deploying 3D interactive branded objects easier, allowing brands to programmatically execute targeted, impactful and scalable XR campaigns.

Trivver’s revolutionary, patented Branded Smart Objects (BSOs) are 3D objects that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment.

The Trivver XR Ad Exchange (XRAE) is a programmatic solution that lets advertisers create, run and monitor a highly targeted XR ad campaign in near real time, on mobile apps and desktop applications. Trivver enables publishers to monetize XR environments with branded content that is native and organic – eliminating pop-ups, banners and interstitials that are disruptive to user experience. The Trivver platform facilitates an organic relationship between brand and consumer.

Contact:

Affect
Nicole Sullivan, 212-398-9680
trivver@affect.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye